# Immunogenicity risk assessment of novel modalities using new approach methodologies

Source: [nature.com](https://www.nature.com/articles/s41573-026-01562-9) · 2026-11-13 · Medicine
Page: https://themorning.science/story/immunogenicity-risk-assessment-of-novel-modalities-using-new-approach-methodolog-1267f51c4aeb9bb6
Kind: research · Impact: medium

## In brief

- Published online in Nature Reviews Drug Discovery on 13 November 2026.
- Covers immunogenicity risk assessment of novel therapeutic modalities such as cell therapies and gene editors.
- Notes that unwanted immune responses limit the clinical progression of these modalities.

## Why it matters

Unwanted immune responses can slow or block the clinical development of promising cell therapies and gene editors, so better methods for assessing that risk matter to drug developers and clinical researchers.

## Timeline

- 2026-11-13: Published online in Nature Reviews Drug Discovery

## Coverage

- [Immunogenicity risk assessment of novel modalities using new approach methodologies](https://www.nature.com/articles/s41573-026-01562-9) — nature.com, 2026-11-13

Tags: immunogenicity, cell therapy, gene editing, drug development, risk assessment

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science